Phase 2 study evaluated safety, tolerability, and preliminary evidence of efficacy of Evenamide (NW-3509) as an add-on to antipsychotics in patients with schizophrenia
Milan,
Milan, Italy, March 2, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the
Milan, Italy and Morristown, NJ, USA, February 21, 2017 - Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for
Milan – January 10, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Milan, Italy and Morristown, NJ, USA, January 3, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for
Milan, Italy – December 23, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Milan, Italy – October 21, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
